Emerging therapeutic platforms
Emerging field of therapeutics, cell, and gene therapies can be impactful in diseases currently deemed untreatable. Opportunities include discovery and development of new drug candidates, platform services to support R&D and manufacturing, as well as the manufacturing and supply chain infrastructure to support large scale production of these treatments.
Our approach
Our approach is rooted in a deep understanding of the healthcare industry and a commitment to making a positive impact. We are currently focused on investing in companies that:
Significantly enhance patient outcomes
We support companies that are dedicated to advancing research and development in healthcare, paving the way for development of new healthcare products, treatments, therapies and cures.
Involve a substantial ‘Make-in-India’ component
We seek out companies which are focused on manufacturing top-notch healthcare products for domestic as well as global markets.
Harness technology to augment healthcare delivery
We intend to invest in companies that utilize advanced technologies like artificial intelligence, machine learning and data analytics to improve efficiency of healthcare delivery and outcome. In particular, we are keen on digital health concepts which focus on developing therapeutic ideas, analyzing medical data, and identifying patterns.
Perspectives
What we’re reading.
Perspectives
Superfluid Dx - Leveraging cf-mRNA for early disease detection
Superfluid Dx - Leveraging cf-mRNA for early disease detection
Perspectives
Announces Substantial Expansion of Research Campus
Adimab
Announces Substantial Expansion of Research Campus
Perspectives
Provides Year-End Update on 2023 Partnership Activities
Adimab
Provides Year-End Update on 2023 Partnership Activities
Perspectives
Gene, Cell, + RNA Therapy Landscape Report
American Society
Gene, Cell, + RNA Therapy Landscape Report
Perspectives
Announces Oversubscribed $165 Million Series C Financing
Bicara Therapeutics
Announces Oversubscribed $165 Million Series C Financing
Perspectives
Presents Updated Interim Data from Ongoing Phase 1/1b Study of BCA101 in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) at ESMO Congress 2023
Bicara Therapeutics
Presents Updated Interim Data from Ongoing Phase 1/1b Study of BCA101 in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) at ESMO Congress 2023
Perspectives
First-in-class Bifunctional EGFR/TGF-β Inhibitor, BCA101, Demonstrates 65% ORR in Combination with Pembrolizumab in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Bicara Therapeutics
First-in-class Bifunctional EGFR/TGF-β Inhibitor, BCA101, Demonstrates 65% ORR in Combination with Pembrolizumab in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Perspectives
Treating Troubling Tumors: CAR T Therapy For Aggressive Childhood T Cell Leukemia
Forbes
Treating Troubling Tumors: CAR T Therapy For Aggressive Childhood T Cell Leukemia
Perspectives
WRQ Sciences and Superfluid Dx., Inc. Announce Completion of Oversubscribed Series A Financing in Breakthrough Alzheimer's Disease Diagnostic Company Superfluid Dx
PR Newswire